1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Product Name: Minocin Intravenous  
Common Name: Not available  
Chemical Name: Not applicable  
Synonyms: Not available  
Product Use: Pharmaceutical product  
Classification: Anti-infective Agent  
Supplier: Wyeth  
P.O. Box 8299  
Philadelphia, PA 19101 USA.  
Telephone: 1-610-688-4400  

Emergency Telephone Number:  
Chemtrec USA, Puerto Rico, Canada 1-800-424-9300  
Chemtrec International 1-703-527-3887

2. COMPOSITION/INFORMATION ON INGREDIENTS

3. HAZARDS IDENTIFICATION

Potential Physical Hazards: Powders and solids are presumed to be combustible.

Potential Health Effects

<table>
<thead>
<tr>
<th>Potential Health Effects</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Eyes</td>
<td>Not available</td>
</tr>
<tr>
<td>Skin</td>
<td>Not available</td>
</tr>
<tr>
<td>Inhalation</td>
<td>Not available</td>
</tr>
<tr>
<td>Ingestion</td>
<td>The most common effects may include photosensitivity, central nervous system effects (lightheadedness, dizziness, vertigo), superinfection, nausea, vomiting, intracranial hypertension, and hepatotoxicity. May cause cancer. May cause harm to the unborn child. May cause harm to breastfed babies. Please see Patient Package Insert for further information.</td>
</tr>
</tbody>
</table>

Therapeutic Target Organ(s): None

Potential Environmental Effects: There is no known ecological information for this product.
4. FIRST AID MEASURES

Eye Contact  
In the case of contact with eyes, rinse immediately with plenty of water for 15 minutes and seek medical advice.

Skin Contact  
Take off contaminated clothing and shoes immediately. Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.

Inhalation  
Move to fresh air. Artificial respiration and/or oxygen may be necessary. If symptoms persist, call a physician.

Ingestion  
If symptoms persist, call a physician. Do not induce vomiting without medical advice. Never give anything by mouth to an unconscious person.

5. FIRE-FIGHTING MEASURES

Flammable Properties
Not flammable

Extinguishing Media

Suitable Extinguishing Media  
Use water spray, foam, dry chemical or carbon dioxide.

Unsuitable Extinguishing Media  
Do NOT use water jet.

Fire Fighting  
Evacuate area and fight fire from a safe distance. Cool closed containers exposed to fire with water spray. In the event of fire and/or explosion do not breathe fumes.

Hazardous Combustion Products  
Carbon oxides, nitrogen oxides.

Protective Equipment and Precautions for Firefighters  
In the event of fire, wear self-contained breathing apparatus and special protective equipment for fire fighters.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions  
Refer to protective measures listed in Sections 7 and 8.

Environmental Precautions  
Prevent product from entering drains. Local authorities should be advised if a significant spill cannot be contained.

Methods for Containment  
Not available

Methods for Cleaning up  
Take up mechanically and collect in suitable container for disposal. Clean contaminated surface thoroughly. Avoid formation of dust and aerosols.

7. HANDLING AND STORAGE

Handling  
For personal protection see Section 8. Handle in accordance with good industrial hygiene and safety practice. Skin should be washed after contact. Avoid formation of dust and aerosols.

Storage  
No special safety precautions required. Keep container tightly closed.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Common Name</th>
<th>Exposure Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minocycline Hydrochloride</td>
<td>200 mcg/m³</td>
</tr>
</tbody>
</table>
Engineering Controls

Apply technical measures to comply with the occupational exposure guideline. Local exhaust ventilation is needed for limited open handling or where aerosols may be generated.

Personal Protective Equipment

**Eye/face Protection**
Provide eye protection based on risk assessment.

**Skin Protection**
Wear nitrile or latex gloves. Wear protective garment.

**Respiratory Protection**
Base respirator selection on a risk assessment.

**General Hygiene Considerations**
When using, do not eat, drink or smoke. General industrial hygiene practice. Wash hands before breaks and at the end of workday.

**Other**
Limit access to only personnel trained in the safe handling of this material. Consult a health and safety professional for specific PPE, respirator, and risk assessment guidance.

---

### 9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Appearance</th>
<th>Pharmaceutical powder</th>
<th>Physical State</th>
<th>Solid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Color</td>
<td>Various</td>
<td>Odor</td>
<td>Not available</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>Not available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>Not available</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Specific Gravity | Not applicable | Water Solubility | Not available |
| Solubility       | Not applicable | Evaporation Rate  | Not applicable |
| Partition Coefficient | Not available | Vapor Density | Not applicable |
| (n-octanol/water) |                |                |       |
| Vapor Pressure   | Not applicable |                |       |

| Boiling Point    | Not applicable | Autoignition Temperature | Not applicable |
| Flash Point      | Not applicable | Method                   | None |
| Melting Point    | Not available  |                          |       |
| Flammability Limits in Air | Upper Not applicable | Lower Not applicable |       |
| Explosion Limits | Upper Not applicable | Lower Not applicable |       |

---

### 10. STABILITY AND REACTIVITY

**Chemical Stability**
Stable at room temperature.

**Conditions to Avoid**
No data available.

**Materials to Avoid**
No materials to be especially mentioned.

**Hazardous Decomposition Products**
None under normal use.

**Possibility of Hazardous Reactions**
None under normal use.

---

### 11. TOXICOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

**Acute Toxicity**

Minocycline Hydrochloride
**Multiple Dose Toxicity**

Minocycline Hydrochloride

No Toxicologic Effect

Dose/Species/Study Length: This compound was tolerated in rats in repeat-dose toxicity studies for 5 months at low dosage; higher doses caused liver toxicity. This compound was tolerated in dogs in repeat-dose toxicity studies for 5 months at low dosage; high doses caused blood effects, anorexia, body weight loss, thyroid pigmentation, thyroid hyperplasia, and skeletal discoloration.

**Maximum Tolerated Dose (MTD), Oral**

Minocycline Hydrochloride

Carcinogenicity: In long-term carcinogenicity studies in rats, dietary administration of this compound revealed an evidence of thyroid tumor production. Thyroid hyperplasia was also found in rats and dogs treated with this compound.

Genetic Toxicity: Not tested; positive results in *in vitro* mammalian cell assays have been reported for related compounds.

Reproductive Toxicity: General reproduction and fertility studies have been conducted and revealed an evidence of impaired fertility in male rats.

Developmental Toxicity: The teratogenic potential of this compound was assessed in the mouse, rat, rabbit, dog, and monkey and revealed an evidence of adverse effects on skeletal development at maternally toxic doses. This compound crosses the placenta and may cause fetal harm.

Minocycline Hydrochloride

Target Organ(s) of Toxicity: No data available

---

**12. ECOLOGICAL INFORMATION**

The following effects are based on the Active Pharmaceutical Ingredient.

**Chemical Fate Information**

Not available

**Ecotoxicity**

Not available

---

**13. DISPOSAL CONSIDERATIONS**

**Waste Disposal Method**

Dispose of in accordance with local and national regulations.

---

**14. TRANSPORT INFORMATION**

**Transport Information**

This material is not classified as hazardous for transport.
15. REGULATORY INFORMATION

According to present data no classification and labeling is required according to Directives 67/548/EEC or 1999/45/EC.

16. OTHER INFORMATION

Prepared By Wyeth Department of Environment, Health & Safety
Format This MSDS was prepared in accordance with Directive 2001/58/EC.
List of References See Patient Package Insert for more information.
Revision Summary Not applicable

Disclaimer:
The information, data, recommendations, and suggestions appearing in this material safety data sheet (MSDS) and/or in materials regarding our active pharmaceutical ingredients (APIs) or products are based upon tests and data believed to be reliable as of the date of publication. NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR ANY OTHER WARRANTY IS MADE WITH REGARD TO THE INFORMATION PROVIDED IN THE MSDS, REGARDING THE API, OR THE PRODUCT TO WHICH THE INFORMATION PERTAINS. Accordingly, Wyeth will not be responsible for any damages resulting from use of, or reliance upon, this information as conditions of use are beyond our control. Users are responsible for assuring the safety of their workers and safe operating conditions, and for determining whether the API or product is suitable for their particular purposes. Users shall assume all risks of their use, handling, and disposal of the API and/or product in accordance with all appropriate and applicable regulations. This information relates only to the API or product designated herein, and does not relate to its use in combination with any other API, material, product, or process. No permission is granted for the use of any API or product in a manner that might infringe on existing patents.

End of MSDS